Ocata Therapeutics Inc fka OCAT

[Han2004fl]

not sure I get you on this. First you won't just get a run of .25 on 100K at lower price as easily as .25 on 5K shares at higher price.

I believe that after the uplisting on Nasdaq, there will be a surge in pps (adjusted to the current share price) as institutional investors will want in early before price moves up. This is where the current investors will get the most rewards. Once all institutional investors get in, pps will stable for awhile till more developments come. Once ACTC can market their products, we are going to see a huge move.

I read it somewhere recently that it costs about $80 million in R&D a year to bring a new drug into the market and get FDA's approval. ACTC has been doing it for much less and basically NO competitors.

The side of the market on one product alone in USA is $50 billion a year.

To me, this company's market cap is only $220 million. They are a year away from marketing their products (or even faster if FDA agree). It's NO BRAINER!